ArticleJournal of cancer research and clinical oncology2023

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.

Sena Valcarcel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.